Back to News
Market Impact: 0.35
CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates
Source: zacks.com
Healthcare & BiotechCorporate EarningsCompany FundamentalsRegulation & Legislation
CRISPR Therapeutics reported Q3 sales above expectations, with Casgevy sales surging. The company also expanded pediatric approvals and advanced multiple clinical programs; the article provides no sales figures or approval details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
CRSP0.75
More News
- Citizens reiterates CRISPR Therapeutics stock rating on Casgevy sales
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- 5 things to watch on Election Day as Democrats push for control of Congress
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?
- Equity Research Automation Statistics: A 2026 Evidence Check